Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and ...
Liquidia (LQDA) rebounds after YUTREPIA FDA approval and $51.7M sales, but inventory effects, demand uncertainty, and patent ...
Thank you, Bob, and good morning, everyone. As we enter the post-pandemic era of Paychex, we are off to a good start in ...
Drivers and fleets have been warned to be on their guard against a new wave of AI-powered phone scams. Front Line Sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback